<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01520116</url>
  </required_header>
  <id_info>
    <org_study_id>ATS907-201</org_study_id>
    <nct_id>NCT01520116</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension</brief_title>
  <official_title>A Phase 1/2a Randomized, Investigator-masked, Placebo- and Active-controlled, Dose-ranging Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altheos, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altheos, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized dose-ranging study will evaluate the safety, tolerability, and preliminary
      efficacy (reduction in intraocular pressure) of multiple dose levels of ATS907, vehicle, or
      latanoprost in subjects with primary open angle glaucoma or ocular hypertension. In the first
      portion, approximately 75 subjects will be randomized to receive either ATS907 or vehicle eye
      drops for up to 28 days, administered both once and twice daily. In the second portion, up to
      180 subjects will be randomized to receive either ATS907 or latanoprost for up to 28 days.
      Plasma pharmacokinetics will also be evaluated during the first portion of the study.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Intraocular Pressure from Baseline</measure>
    <time_frame>Stage 1: Days 14, 21 and 28; Stage 2: Day 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed Intraocular Pressure and % change from Baseline IOP</measure>
    <time_frame>Stage 1: Days 0, 1, 4, 14, 21, 28; Stage 2: Days 0, 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean observed, mean change from Baseline and mean % change from Baseline for the mean diurnal IOP</measure>
    <time_frame>Stage 1: Days 0, 1, 4, 14, 21, 28; Stage 2: Days 0, 4</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Stage 1 - Arm 1 - Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 - Arm 2 - Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 - Arm 3 - Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 - Arm 4 - Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 - Arm 5 - Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 - Arm 3 -Timoptic 0.5% BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 1 - ATS907 - Dose 1</intervention_name>
    <description>QD and/or BID dosing for 28 days</description>
    <arm_group_label>Stage 1 - Arm 1 - Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 1 - ATS907 - Dose 2</intervention_name>
    <description>QD and/or BID dosing for 28 days</description>
    <arm_group_label>Stage 1 - Arm 2 - Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 1 - ATS907 - Dose 3</intervention_name>
    <description>QD and/or BID dosing for 28 days</description>
    <arm_group_label>Stage 1 - Arm 3 - Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 1 - ATS907 - Dose 4</intervention_name>
    <description>QD and/or BID dosing for 28 days</description>
    <arm_group_label>Stage 1 - Arm 4 - Dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 1 - Vehicle</intervention_name>
    <description>QD and/or BID dosing for 28 days</description>
    <arm_group_label>Stage 1 - Arm 5 - Vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 2 - ATS907 - Dose A - to be selected based on Stage 1</intervention_name>
    <description>QD and/or BID dosing for 4 days</description>
    <arm_group_label>Stage 2 - Arm 1 - Dose A - to be selected based on Stage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stage 2 - ATS907 - Dose B - to be selected based on Stage 1</intervention_name>
    <description>QD and/or BID dosing for 4 days</description>
    <arm_group_label>Stage 2 - Arm 2 - Dose B - to be selected based on Stage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timoptic</intervention_name>
    <description>0.5%</description>
    <arm_group_label>Stage 2 - Arm 3 -Timoptic 0.5% BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or greater

          -  Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT) in both eyes

          -  Unmedicated (post-washout) IOP ≥ 23 mm Hg at 2 eligibility visits: 07:00-09:00 hr on
             Days O and 1 and IOP &gt; 18 mm Hg at 15:00-17:00 on Day 0 (Stage 1)

          -  Unmedicated (post-washout) IOP criteria after wash out &lt; 32 mm Hg OU at all times
             points (Stage 1)

          -  Unmedicated (post-washout) IOP ≥ 24 mm Hg at 2 eligibility visits: 07:00-09:00 hr on
             Days O and 1 and IOP &gt; 21 mm Hg at 9:00-17:00 on Day 0 (Stage 2)

          -  Unmedicated (post-washout) IOP criteria after wash out &lt; 36 mm Hg OU at all times
             points (Stage 2)

          -  Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye
             (equivalent to 20/200)

          -  Must be willing to discontinue the use of all ocular hypotensive medications in both
             eyes prior to and during the entire course of the study

        Exclusion Criteria:

          -  Ophthalmic (in either eye)

               1. Glaucoma: pseudoexfoliation, steroid induced, pigment dispersion glaucoma, and or
                  history of angle closure. Previous glaucoma intraocular surgery or glaucoma laser
                  procedures in study eye(s). Prior laser glaucoma surgery is permitted in the non
                  study eye

               2. Refractive surgery in study eye (e.g., radial keratotomy, PRK, LASIK, etc.)

               3. Cataract surgery and or other intraocular surgery within three months prior to
                  Screening in either eye.

               4. History within 3 months prior to Screening of clinically significant moderate or
                  severe chronic or active ocular infection, inflammation, blepharitis, dermatitis,
                  uveitis or conjunctivitis.

               5. Clinically significant corneal dystrophy, epithelial and or endothelial disease,
                  corneal irregularities and or scarring such that reliable applanation tonometry
                  would prevented.

               6. Contact lens wear during the duration of the study.

               7. Clinically significant ocular disease (e.g. diabetic retinopathy, macular
                  degeneration, or uveitis) which might interfere or progress during the study.

               8. Central corneal thickness &lt; 480 or &gt; 600 μm in the study eye

          -  Systemic

               1. Clinically significant abnormalities in laboratory tests at screening.

               2. Clinically significant systemic disease (e.g., uncontrolled diabetes,
                  uncontrolled hyper or hypotension, hepatic, renal, endocrine or cardiovascular
                  disorders). Participation in any investigational study within the past 30 days.

               3. Changes of systemic medication that could have a substantial effect on IOP and or
                  systemic blood pressure within 7 days prior to Baseline (Day 0).

               4. Women of childbearing potential who are pregnant, nursing, planning a pregnancy,
                  or not using a medically acceptable form of birth control. An adult woman is
                  considered to be of childbearing potential unless she is one year post-menopausal
                  or three months post-surgical sterilization. All females of childbearing
                  potential must have a negative urine pregnancy test result at the Screening visit
                  and a negative urine and serum pregnancy at Baseline (Day 0) and must not intend
                  to become pregnant during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Wirostko, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Altheos, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Joseph</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2012</study_first_posted>
  <last_update_submitted>October 30, 2012</last_update_submitted>
  <last_update_submitted_qc>October 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

